DTIC (NSC-45388) studies in the southwest oncology group.
In a phase I study, the best antitumor/toxicity ratio for DTIC was reported to be at a dose of 250 mg/m2/day X 5 repeated at 28-day intervals. Nausea, vomiting, leukopenia, and thrombocytopenia were the major toxic effects noted. The best responses were seen in disseminated melanoma (19%), various sarcomas (22%), and Hodgkin's disease. A subsequent phase II study in refractory lymphomas showed a response rate in Hodgkin's disease of 56%. In disseminated melanomas, DTIC was then combined with vincristine and BCNU and demonstrated a response rate of 23% which did not improve with the addition of chlorpromazine (23%). A response rate of 31% was seen with the combination of DTIC, BCNU, and hydroxyurea which did not improve with the addition of vincristine (30%). Responders had a more significant survival rate as compared to nonresponders.
D002330:Carmustine / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000627:therapeutic use* / Q000633:toxicity; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008223:Lymphoma / Q000188:drug therapy*; D008545:Melanoma / Q000188:drug therapy*; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced; D014226:Triazenes / Q000627:therapeutic use*; D014750:Vincristine / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D014226:Triazenes; D014750:Vincristine; D003606:Dacarbazine; D002746:Chlorpromazine; D002330:Carmustine